Zhongsu's IPO "suspended". Its core products include modified PC, PC/ABS and other high-performance engineering materials.
"Zhong Su shares IPO "suspended"."
On December 31, Guangdong Zhongshu New Materials Co., Ltd. (referred to as Zhongplastics) IPO status was changed to "suspended". The financial data recorded in Zhongplastics' IPO application documents has expired and needs to be supplemented.
The prospectus shows that Zhongplastics' main business is the research, production, and sales of modified engineering plastics. The company's main products are used in industries such as consumer electronics, energy storage, automotive, home appliances, etc., including end products such as mobile phones, smart wearable devices, tablets, laptops, Bluetooth speakers, energy storage power supplies, new energy vehicles, and home appliances. The company follows a product differentiation strategy based on the fast iteration of products in industries such as consumer electronics and the high quality requirements, focusing on the development of high value-added modified engineering plastic products to meet the personalized material needs of downstream products.
The company insists on independent research and development and continues to enrich its product series. Its core products include modified PC, PC/ABS, PA, PPA, PBT, PET, and other high-performance engineering materials. For customer products with specific requirements for electrical interconnection, low dielectric, high temperature resistance, waterproof heat dissipation, the company has developed special functional materials such as laser direct structuring (LDS) materials, nano injection molding (NMT) special engineering materials, and ultra-high temperature resistant nylon materials.
The specific introduction of the company's main business products is shown in the table below:
Financially, in the fiscal years 2022, 2023, 2024, and the first three months of 2025, Zhongplastics achieved operating revenues of approximately 493 million, 537 million, 700 million, and 152 million RMB respectively; during the same period, the company's net profits were approximately 51.71 million, 78.998 million, about 100 million, and 25.702 million RMB respectively.
Related Articles

ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.
ZHONGZHIPHARM(03737) issues a profit warning, expecting a decrease in annual net profit of no less than 70%.

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


